Skip to main content

Table 4 Response in measurable lesions

From: A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Groups N CR PR SD PD ORR (%) DCR (%) P value*
All patients 45 0 14 22 9 31.8 77.3 0.54
No ascites 28 0 11 14 3 39.2 89.2  
Small to moderate ascites 12 0 2 6 4 16.7 66.7  
Massive ascites 5 0 1 2 2 20.0 60.0  
  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate (CR + PR + SD)
  2. *Comparison of ORR between 3 groups